In recent years, the correlation between nasal diseases and bronchial asthma has attracted much attention from the medical community, and in 2001, the concept of allergic rhinitis and asthma as a respiratory tract and a disease was internationally recognized. More and more studies have shown that allergic rhinitis is a risk factor for the pathogenesis and development of asthma, and is closely related to the refractory nature of asthma. Early intervention for allergic rhinitis also greatly influences asthma regression and treatment outcomes. Both allergic rhinitis and bronchial asthma are common respiratory allergic diseases in children, which seriously affect children’s health. Pediatricians and otolaryngologists are increasingly recognizing the benefits of collaboration between the two disciplines. Epidemiological studies have shown a close relationship between childhood bronchial asthma and allergic rhinitis, with 60% of asthmatics having allergic rhinitis and up to 80% of asthmatic children having allergic rhinitis. In the United States, asthma is comorbid in about 20% to 38% of children with allergic rhinitis. Numerous studies have found that the presence of childhood allergic rhinitis is a risk factor for the persistence of asthma in children, even into adulthood, and increases the likelihood of new asthma attacks after childhood. Anatomically, the lumen between the upper and lower airways is connected and the mucosa is continuous. The surface is covered with pseudo-complex ciliated columnar epithelium and a continuous basement membrane. Any part of the respiratory tract subjected to some kind of stimulus, such as allergens, pollutants, viruses, bacteria, etc., can produce similar histologic changes and similar but characteristic clinical manifestations: sneezing, coughing, nasal congestion, asthma and other symptoms. In terms of clinical manifestations, most asthmatic children who experience wheezing are preceded by symptoms such as nasal itching, sneezing, nasal congestion, and runny nose. Allergic rhinitis and bronchial asthma are both allergic diseases and are susceptible to a variety of internal and external factors, including external allergens, air pollution, passive smoking, atopic constitution, and a family history of atopic disease. Synergistic treatment of asthma with allergic rhinitis has received extensive attention worldwide in recent years. A large number of studies have demonstrated that active treatment of allergic rhinitis can effectively improve the subjective and objective symptoms of asthma and significantly reduce the number of acute asthma attacks. The severity of asthma exacerbations is reduced, and the burden of asthma disease can be reduced by early intervention for allergic rhinitis. Poorly controlled asthma is associated with allergic rhinitis, anti-asthma prescribing increases with the severity of allergic rhinitis, and allergic rhinitis is associated with severe asthma, difficult-to-control asthma, and quality of life in asthma patients. According to the guideline “Allergic Rhinitis and its Impact on Asthma”, the principles of treatment for allergic rhinitis include environmental control (avoidance of allergens), medication, immunotherapy and patient education. The principles of treatment are similar to those of asthma. There is no doubt that avoidance of exposure to allergens is the ideal control measure for childhood allergic diseases, but avoidance of inhalant allergens is often difficult to achieve, whereas avoidance of allergenic foods is possible. Early intervention to reduce pediatric food allergic reactions can help to improve the immune status of the body, promote the Thl/Th2 balance of the machine, and reduce the occurrence of allergic diseases. Local administration of inhaled glucocorticoids is currently the first line of treatment for asthma. Similarly, the topical administration of glucocorticoids should be emphasized in the treatment of allergic rhinitis. Nasal corticosteroid therapy suppresses the seasonal increase in bronchial responsiveness to acetylmethacholine, which is more pronounced than orally inhaled corticosteroids, and is also effective in seasonal allergic rhinitis. Inhaled steroids for asthma are not a substitute for nasal steroids for allergic rhinitis! For children with asthma associated with allergic rhinitis, nasal topical glucocorticoid inhalation can effectively relieve asthma symptoms, improve the quality of life of children, long-term use of the drug is more significant for the relief of clinical symptoms and airway inflammation. Leukotriene receptor antagonists are new anti-asthma drugs, montelukast used in the treatment of allergic rhinitis in children also received a good effect. The combination of leukotriene receptor antagonist and inhaled corticosteroid can reduce its dosage, significantly improve the efficacy of asthma combined with allergic rhinitis in children, increase the adherence of children, and reduce adverse effects. Specific immunotherapy is the only etiologic treatment that can influence the natural course of allergic disease and prevent the development of allergic rhinitis into asthma or other new allergies. Anti-IgE monoclonal antibodies, a new treatment for asthma, reduce serum free IgE levels and improve symptoms in the upper and lower airways of allergic rhinitis and asthma. Childhood asthma and allergic rhinitis are closely related in terms of epidemiology, pathogenesis, diagnosis and treatment, and prognosis. Clarifying the relationship between the two is important for the prevention and treatment of both. On the one hand, when the two diseases coexist. Should be treated at the same time, rather than the two diseases in isolation separate treatment; on the other hand, children as a special group, is the early stage of allergic diseases, such as active intervention therapy, can block its development process. Appropriate treatment of allergic rhinitis at an early stage may also have the potential to prevent the further development of asthma.